₹10,000 Monthly SIP in Nippon India Pharma Fund-Growth Plan for 10 Years
If you had started a ₹10,000/month SIP on 18 Aug 2016 and never stopped — through every crash and rally — here is exactly what happened, using Nippon India Pharma Fund-Growth Plan's actual NAV for all 121 installments.
You invested
₹12,10,000
121 installments
Value today
₹31,18,091
18 Aug 2026
Absolute gain
+₹19,08,091
+157.7%
XIRR (annualised)
17.97%
money-weighted
The journey, month by month
Worst fall on the way
-19.6%
Deepest drop from peak. This is what you had to sit through.
Corrections survived
4
Falls of 10%+ during the period. Every one recovered.
Same SIP in a fixed deposit
₹16,84,458
Modelled at historical FD rates. The fund beat FD by ₹14,33,633.
Year-by-year progress
| Year | Invested | Value | Overall gain |
|---|---|---|---|
| Year 1 (18 Aug 2017) | ₹1,30,000 | ₹1,16,050 | -10.7% |
| Year 2 (20 Aug 2018) | ₹2,50,000 | ₹2,83,852 | +13.5% |
| Year 3 (19 Aug 2019) | ₹3,70,000 | ₹3,63,381 | -1.8% |
| Year 4 (18 Aug 2020) | ₹4,90,000 | ₹7,51,099 | +53.3% |
| Year 5 (18 Aug 2021) | ₹6,10,000 | ₹11,89,974 | +95.1% |
| Year 6 (18 Aug 2022) | ₹7,30,000 | ₹11,94,493 | +63.6% |
| Year 7 (18 Aug 2023) | ₹8,50,000 | ₹16,25,306 | +91.2% |
| Year 8 (19 Aug 2024) | ₹9,70,000 | ₹24,83,369 | +156% |
| Year 9 (18 Aug 2025) | ₹10,90,000 | ₹27,25,645 | +150.1% |
| Year 10 (18 Aug 2026) | ₹12,10,000 | ₹31,18,091 | +157.7% |
Best year of the journey: Year 4 (+55.4% market move) · Toughest year: Year 1 (-10.7%)
Wealth Time Machine
Watch this exact journey as a 60-second cinematic replay
Every crash headline, every recovery — with your money in it.
Try a different amount
Try a different duration
Past performance does not guarantee future returns. This page shows the historical result of the stated SIP using Nippon India Pharma Fund-Growth Plan's published NAV (source: AMFI) between 18 Aug 2016 and 18 Aug 2026; it is educational research, not investment advice. FD comparison is modelled at historical average FD rates. Mutual fund investments are subject to market risks.